Stock Detail
ARCA BIOPHARMA INC
Biotechnology
ABIO @ Yahoo Finance | ABIO Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $1.71 | $2.45 | $0.52 | 43.70% | 0.00 | $1.19 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $1.12 | $1.11 | 3.94M | 17.98M | 26,802.5 | -3.05 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 3.10 | 2.41 | 1.76 | 1.07 | 0.42 |
Stock Profile
ARCA biopharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of genetically-targeted therapies for heart failure and other cardiovascular diseases in the United States. The companyÂ's lead product candidate includes Gencaro, a pharmacologically beta-blocker and mild vasodilator for the treatment of chronic heart failure and other indications. It also focuses on the development of NU172, a short-acting anticoagulant used during medical or surgical procedures, which has completed Phase Ib clinical study. ARCA biopharma has a collaboration agreement with LabCorp to develop the Gencaro Test, a companion test for the genetic markers that predict clinical response to Gencaro. The company is headquartered in Broomfield, Colorado.